title: [Hyperkalemia : what can we expect from new potassium-lowering drugs?].
abstract: Hyperkalemia is a common clinical problem. While several options are available to treat acute hyperkalemia, there are few options for long-term treatment. The use of oral potassium binders might be such an option. Sodium zirconium cyclosilicate and patiromer are two new oral potassium binders awaiting approval. The efficacy of these novel potassium-lowering agents were tested in several phase 3 short-term studies published in late 2014.
authors.affiliation: Klinik für Nieren- und Hochdruckkrankheiten, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland, schmitt.roland@mh-hannover.de.
authors.forename: R
authors.initials: R
authors.lastname: Schmitt
mesh_terms: D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D006801:Humans; D006947:Hyperkalemia / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D011108:Polymers / Q000008:administration & dosage* / Q000009:adverse effects; D017640:Silicates / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D017640:Silicates; C568789:patiromer; C000597310:sodium zirconium cyclosilicate